trial

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

NCTId NCT01323205
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 100 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2012-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
100 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-05
Primary completion
2012-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
JNJ-40411813Antipsychotic medication

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Linked catalysts

1
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of J — primary completion2012-11

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE2
Primary Completion Date
2012-11
Status
COMPLETED
relationships
The graph out of here
drug
JNJ-40411813
drug
Antipsychotic medication
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication